Squarepoint’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141M | Buy |
426,723
+75,754
| +22% | +$25.8M | 0.17% | 100 |
|
|
2025
Q4 | $140M | Buy |
350,969
+205,404
| +141% | +$90.9M | 0.15% | 128 |
|
|
2025
Q3 | $66.4M | Buy |
145,565
+143,119
| +5,851% | +$58.3M | 0.07% | 333 |
|
|
2025
Q2 | $798K | Sell |
2,446
-3,822
| -61% | -$1.06M | ﹤0.01% | 2869 |
|
|
2025
Q1 | $1.69M | Sell |
6,268
-121,429
| -95% | -$31.2M | ﹤0.01% | 2230 |
|
|
2024
Q4 | $30M | Buy |
127,697
+84,996
| +199% | +$22.4M | 0.03% | 573 |
|
|
2024
Q3 | $11.7M | Sell |
42,701
-56,093
| -57% | -$14.6M | 0.02% | 875 |
|
|
2024
Q2 | $24M | Sell |
98,794
-481,647
| -83% | -$76M | 0.04% | 506 |
|
|
2024
Q1 | $86.7M | Buy |
580,441
+244,615
| +73% | +$40.8M | 0.15% | 115 |
|
|
2023
Q4 | $64.3M | Buy |
335,826
+98,192
| +41% | +$16.7M | 0.12% | 166 |
|
|
2023
Q3 | $42.1M | Buy |
237,634
+70,011
| +42% | +$13.4M | 0.1% | 205 |
|
|
2023
Q2 | $31.8M | Buy |
167,623
+34,395
| +26% | +$6.82M | 0.1% | 214 |
|
|
2023
Q1 | $26.7M | Buy |
133,228
+131,019
| +5,931% | +$27.5M | 0.11% | 198 |
|
|
2022
Q4 | $525K | Sell |
2,209
-35,541
| -94% | -$7.58M | ﹤0.01% | 2259 |
|
|
2022
Q3 | $7.56M | Sell |
37,750
-87,350
| -70% | -$16.7M | 0.04% | 551 |
|
|
2022
Q2 | $18.2M | Buy |
125,100
+87,662
| +234% | +$12.4M | 0.1% | 220 |
|
|
2022
Q1 | $6.11M | Buy |
+37,438
| New | +$5.7M | 0.03% | 639 |
|
|
2021
Q1 | – | Sell |
-23,308
| Closed | -$3.51M | – | 3058 |
|
|
2020
Q4 | $3.03M | Sell |
23,308
-4,183
| -15% | -$559K | 0.02% | 714 |
|
|
2020
Q3 | $4M | Buy |
27,491
+24,359
| +778% | +$3.46M | 0.05% | 404 |
|
|
2020
Q2 | $464K | Sell |
3,132
-8,604
| -73% | -$1.16M | 0.01% | 1355 |
|
|
2020
Q1 | $1.28M | Sell |
11,736
-66,557
| -85% | -$7.68M | 0.03% | 619 |
|
|
2019
Q4 | $9.02M | Buy |
+78,293
| New | +$7.81M | 0.05% | 336 |
|
|
2019
Q3 | – | Sell |
-21,792
| Closed | -$1.58M | – | 2310 |
|
|
2019
Q2 | $1.58M | Buy |
21,792
+9,472
| +77% | +$727K | 0.02% | 982 |
|
|
2019
Q1 | $1.15M | Buy |
+12,320
| New | +$1.03M | 0.01% | 1030 |
|
|
2018
Q4 | – | Sell |
-74,930
| Closed | -$6.56M | – | 1907 |
|
|
2018
Q3 | $6.56M | Sell |
74,930
-15,188
| -17% | -$1.53M | 0.08% | 324 |
|
|
2018
Q2 | $8.88M | Buy |
90,118
+61,372
| +213% | +$6.09M | 0.12% | 260 |
|
|
2018
Q1 | $3.42M | Buy |
+28,746
| New | +$3.71M | 0.05% | 406 |
|
|
2017
Q3 | – | Sell |
-26,530
| Closed | -$2.12M | – | 1592 |
|
|
2017
Q2 | $2.12M | Buy |
26,530
+15,730
| +146% | +$1.01M | 0.04% | 505 |
|
|
2017
Q1 | $554K | Sell |
10,800
-700
| -6% | -$32.4K | 0.02% | 819 |
|
|
2016
Q4 | $431K | Buy |
11,500
+4,500
| +64% | +$188K | 0.02% | 922 |
|
|
2016
Q3 | $474K | Buy |
+7,000
| New | +$494K | 0.03% | 583 |
|
|
2016
Q2 | – | Sell |
-8,000
| Closed | -$502K | – | 1080 |
|
|
2016
Q1 | $502K | Buy |
8,000
+2,800
| +54% | +$186K | 0.04% | 627 |
|
|
2015
Q4 | $490K | Buy |
+5,200
| New | +$482K | 0.05% | 549 |
|
Other funds holding ALNY
VPM
VCM
Squarepoint's ALNY Position: Q1 2026 in Review
Squarepoint increased its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q1 2026, buying an estimated $25.8M and bringing the position to 426,723 shares worth $141M. The position accounts for 0.17% of the portfolio, ranked #100.
Squarepoint first reported a position in ALNY in Q4 2015 and has held it in 33 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Squarepoint held 426,723 shares of Alnylam Pharmaceuticals worth $141M as of Q1 2026.
- Squarepoint bought 75,754 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
- Alnylam Pharmaceuticals made up 0.17% of Squarepoint's portfolio in Q1 2026, its #100 holding.
- Squarepoint first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.